Innovation

A new paper sets out an insurance model as part of a global solution to incentivise R&D for new antibiotics to tackle multi-drug resistance. It offers (i) a reasonable return on R&D; (ii) risk mitigation for payers, providers and manufacturers, (iii) stewardship by delinking revenues from volume of use, and (iv) conservation of antibiotic effectiveness by ensuring the continued availability of new antibiotics in the long-term.

On Tuesday 19th September 2017, Professor Frank Lichtenberg from Columbia University will lead an OHE Lunchtime Seminar on the topic of: How cost-effective are new cancer drugs in the U.S.?

In November 2016 Professor Dame Sally Davies delivered the 23rd OHE Annual Lecture on the topic of: Ten Years of the NIHR: Achievements and Challenges for the Next Decade. The lecture is now available as a publication, available for download.

Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers and HTA bodies.

OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This research looked at the health, economic and scientific impact of Oxford BRC’s research activity.

Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as a regional “pull” incentive.

Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the 2016 ICER Membership Policy Summit.

A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice” between 2007 and mid-2016. The level of patient access associated with these decisions has also been assessed.

The Office of Health Economics (OHE) and the Swedish Institute for Health Economics (IHE) publish a report evaluating the efficiency of resource allocation in cancer care across Europe.

OHE’s Amanda Cole co-authors a new publication on the headroom approach, which can help assess the commercial value and viability of medical device development.

Pages

Subscribe to RSS - Innovation